ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,307Medicare Part D Prescriptions Filled, Including Refills

Rank: 379 out of 2680

$310K Total Retail Price of All Prescriptions

Rank: 885 out of 2680

287 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
94% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 287 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

18% of this provider’s 287 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

0% of this provider’s 6,929 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$42 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
FUROSEMIDE 317 314 1 7
LEVOTHYROXINE SODIUM 296 295 2 4
RANITIDINE HCL 280 276 3 35
AMLODIPINE BESYLATE 213 192 4 3
MIRTAZAPINE 190 190 5 48
HYDROCODONE-ACETAMINOPHEN 186 178 S3 6 13
METOPROLOL TARTRATE 178 167 7 8
METFORMIN HCL 171 165 8 6
DONEPEZIL HCL 166 166 9 28
WARFARIN SODIUM 158 152 10 12
PAROXETINE HCL 134 123 11 62
OMEPRAZOLE 132 125 12 2
SILVER SULFADIAZINE 131 131 13 227
LISINOPRIL 122 121 14 5
TAMSULOSIN HCL 120 114 15 25
POTASSIUM CHLORIDE 113 108 16 29
CITALOPRAM HBR 102 96 17 22
LEVETIRACETAM 100 71 18 94
NOVOLIN N 92 92 19 279
TRAZODONE HCL 91 90 20 60
ISOSORBIDE MONONITRATE ER 86 82 21 57
LOVASTATIN 84 83 22 37
TRAMADOL HCL 83 83 23 33
METOPROLOL SUCCINATE 71 65 24 11
ENALAPRIL MALEATE 71 53 24 24
CLONIDINE HCL 70 69 26 84
LIDOCAINE 69 69 27 186
CARVEDILOL 69 61 27 27
RISPERIDONE 67 67 29 67
POLYETHYLENE GLYCOL 3350 65 61 30 55
GLIPIZIDE 61 60 31 71
GABAPENTIN 61 48 31 21
SIMVASTATIN 58 58 33 1
ALBUTEROL SULFATE 57 57 34 97
PREDNISONE 56 55 35 45
OXYBUTYNIN CHLORIDE 56 55 35 189
NAMENDA 55 55 37 43
NYSTOP 55 55 37 183
LANTUS 54 42 39 70
ATORVASTATIN CALCIUM 54 43 39 10
CLOPIDOGREL 53 40 41 30
DILTIAZEM HCL 53 53 41 324
DIOVAN 53 52 41 26
DIVALPROEX SODIUM 50 50 44 90
IPRATROPIUM-ALBUTEROL 50 50 44 110
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 21, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.